Oryzon Genomics ramps up internationalization
The company has named two new independent advisors to its board of directors
Oryzon Genomics has reinforced its board of directors with two international members. The Barcelona-based biotechnology firm has chosen two professionals with extensive experience in the pharmaceutical sector: Russel Greig will chair the Compensations and Nominations Committee and Greg Weaver, the Audit Committee. “They are very experienced, skilled and well-connected directors and will provide insight and drive to our objective of becoming an international champion”, said Oryzon CEO Carlos Buesa.
The decision is aimed at improving corporate governance and transparency and international projection. Oryzon, which is clearly oriented towards internationalization, is also preparing to take the leap to the United States. The company expects to open a headquarters in Boston soon and hopes to go public on the Nasdaq in approximately one year.
Related news: